comparemela.com

Latest Breaking News On - Gensight biologics euronext - Page 5 : comparemela.com

GenSight Biologics: Annual General Meeting on June 21, 2023

Procedures for obtaining preparatory documents for the General Meeting Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on

France generalGensight biologicsGuillaume van renterghemClothilde cailletGensight biologics euronextCorporate communicationsSight biologicsAnnual general meetingFaubourg saint antoineGeneral meetingFrench commercial codeCommercial codeSight biologicMitochondrial targeting sequenceLeber hereditary optic neuropathyGensight biologic

GenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for

France generalJames palmerBernard gillyGensight biologics euronextThomas gidoinClothilde cailletGuillaume van renterghemJeanene timberlakeGensight biologicsCorporate communicationsRegulatory newsSight biologicsRegistration documentDes marchScientific adviceChief executive officer

GenSight Biologics S A : Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023

Paris, France, Wednesday May 10, 2023, 6:00 pm CEST - GenSight Biologics , a biopharma company focused on developing and commercializing innovative gene therapies for retinal. | May 10, 2023

France generalGensight biologicsGensight biologics euronextThomas gidoinBernard gillyWednesday maySight biologicsRegistration documentDes marchScientific adviceChief executive officerChief financial officerAnnual general meetingGensight biologics sa stock exchangePress releaseOr sight fr0013183985

GenSight Biologics Announces the Re-approval of its Full Year 2022 Consolidated Financial Statements

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative

Gensight biologics euronextGensight biologicsGuillaume van renterghemJames palmerClothilde cailletJeanene timberlakeCorporate communicationsEuropean medicines agencyRegulatory newsSight biologicsUniversal registration documentDes marchSight biologicMitochondrial targeting sequenceLeber hereditary optic neuropathyGensight biologic

GenSight Biologics Withdraws its EMA Application for LUMEVOQ

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for

United statesUnited kingdomFrance generalGensight biologics euronextGuillaume van renterghemBernard gillyGensight biologicsClothilde cailletPatrick yuJeanene timberlakeCorporate communicationsPhd cambridge universityEuropean medicines agencyCommittee for advanced therapiesMd university of pittsburgh school medicineCommittee medicinal products for human use

vimarsana © 2020. All Rights Reserved.